LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

29.3 -3.3

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.3

Max

29.73

Belangrijke statistieken
By Trading Economics
Inkomsten	-30M -30M
Verkoop	-26M 77M
Winstmarge	-38.823
Werknemers	524
EBITDA	-12M -8M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+110.72% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-214M 1.4B
Vorige openingsprijs	32.6
Vorige sluitingsprijs	29.3

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

27.895 / 30.16 Steun & Weerstand

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 mei 2026, 23:55 UTC

Winsten

Review & Preview: Still Going Strong -- Barrons.com

8 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 20:49 UTC

Winsten

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mei 2026, 20:25 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Net $115M

8 mei 2026, 19:20 UTC

Marktinformatie

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mei 2026, 19:18 UTC

Winsten

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mei 2026, 19:16 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:08 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:05 UTC

Winsten

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mei 2026, 19:02 UTC

Marktinformatie

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mei 2026, 18:51 UTC

Winsten

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mei 2026, 18:49 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 18:41 UTC

Winsten

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mei 2026, 17:14 UTC

Winsten

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mei 2026, 17:04 UTC

Marktinformatie

Zcash Caps Off Parabolic Week -- Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mei 2026, 15:36 UTC

Marktinformatie

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mei 2026, 15:20 UTC

Marktinformatie

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mei 2026, 15:20 UTC

Marktinformatie

Winsten

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mei 2026, 15:05 UTC

Marktinformatie

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mei 2026, 14:42 UTC

Marktinformatie

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 mei 2026, 14:39 UTC

Marktinformatie

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

110.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.33 USD 110.72%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.